Related Experiment Video
Updated: May 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Hepatocellular carcinoma: towards personalized medicine
Daiki Miki1, Hidenori Ochi, C Nelson Hayes
1Laboratory for Digestive Diseases, RIKEN Center for Genomic Medicine, Hiroshima, Japan.
Genome-Wide Association Studies (GWAS) identified genetic markers associated with hepatocellular carcinoma (HCC) risk. These findings may advance personalized medicine for liver cancer by assessing individual genetic backgrounds.
Area of Science:
- Genetics
- Hepatology
- Oncology
Background:
- Genome-Wide Association Studies (GWAS) and pharmacogenomics are advancing personalized medicine.
- Host genetic factors are crucial for predicting treatment outcomes in chronic hepatitis C virus (HCV) infection.
- Recent GWAS have investigated virus-related hepatocellular carcinoma (HCC) in Asia.
Purpose of the Study:
- To compare results from recent HCC GWAS with previous candidate gene studies.
- To identify genetic variants associated with HCC risk.
- To explore the potential of genetic background in personalized HCC medicine.
Main Methods:
- Review and comparison of published Genome-Wide Association Studies (GWAS) on virus-related HCC.
- Analysis of candidate gene studies.
- Identification of common variants in specific genetic loci.
Main Results:
- A common variant in the DEPDC5 locus was associated with HCV-related HCC.
- Another study identified an association involving the MICA locus in HCC.
- These findings highlight specific genetic markers linked to HCC risk.
Conclusions:
- Further research is needed to elucidate the role of identified single nucleotide polymorphisms (SNPs) in HCC risk.
- Genetic markers can potentially assess individual HCC cancer risk based on genetic background.
- Understanding these genetic associations may reveal novel therapeutic targets for HCC.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
07:25Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery
Published on: August 18, 2023
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer
Pharmacogenomics: Identification of New Drug Targets